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Abstract
Fibroblast growth factor receptor (FGFR) gain-of-function mutations form the pathogenic basis of multiple congenital pathologies. A 
pioneering body of work over the past two decades has established that a unique mutation selection process within the testis likely 
underlies the paternal age effect characteristics of such diseases. This mechanism, analogous to positive selection of mutations promo-
ting proliferation in tumorigenesis, sparked interest in mutation profiling of testicular and other cancers. The resulting discovery of FGFR 
gain-of-function mutations akin to those of congenital syndromes has enabled a novel hypothesis to be born: that mutations represent 
a spectrum of activation. As such, FGFR gain-of-function mutations could be pathogenic not solely in defined monogenic syndromes but 
within myriad disease processes with ‘low activation’ conferring increased disease risk. Do such mutations contribute to multigenic risk 
in multiple pathologies? This review evaluates this hypothesis, alluding to the plausible clinical implications that ensue.
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Introduction
A 31-year-old man with dwarfism; an infant with short arms, 
legs and a clover-leaf skull; premature skull fusion and union 
of the bones of the digits in a still-born child. Achondropla-
sia, thanatophoric dysplasia type II and Apert syndrome res-
pectively, appear to represent grossly varying pathologies at 
the macroscopic scale. However, each illustrates a variant of a 
common pathological theme: fibroblast growth factor receptor 
(FGFR) activating mutations. FGFRs are represented in multiple 
isoforms in the human proteome and they have diverse func-
tions that include cell growth and differentiation and germ cell 
development. These receptors are predominant in embryolo-
gical, neonatal, and renewing tissues.1 The bodies of disease 
with FGFR gain-of-function (GOF) mutations as a pathogenic 
agent provide a plethora of opportunity to firmly establish FGFR 
function.
This literature review will explore the progression of the field 
in characterising the disease mechanisms conferred by such 
mutations. Through analysis of mutation development at the 
molecular and cellular level it will unravel the complex interac-
tions of function in the testis and fetus, thereby establishing 
the concept that FGFR GOF represents a spectrum of activation 
with varying contributions to pathology. Thus, it addresses the 
question of whether such mutations contribute to multigenic 
risk in multiple pathologies.
Methodology
A literature review was performed using PubMed, MEDLINE 
and Embase databases, with the free search terms ‘fibroblast 
growth factor receptor’, ‘gain of function’ and ‘Apert syndrome’ 
Additional relevant papers were retrieved from the references. 
All included articles were in the English language and were 
relevant to FGFR gain-of-function, identification of relation to 
a pathological state, or determination of plausible mutation 
aetiology. 
Too Much of a Good Thing? 
Apert syndrome, an autosomal dominant inherited congenital 
malformation syndrome, is characterised by craniosynostosis 
and syndactyly with a live birth rate of approximately 1 in 
70,000.2 Wilkie et al., 1995 pioneered research into the con-
dition through establishing the molecular basis. By analysing 
non-recombination (alleles with the same arrangement in 
affected offspring as parents) across 4 Apert families, the FG-
F2R locus was implicated as the prime candidate. Amplification 
of FGF2R complimentary DNA (cDNA) from the patients followed 
by sequencing revealed two distinct single point transversions 
at independent loci in the extracellular domain, providing a 
putative genetic basis for the disease.3 These mutations were 
further illustrated to induce GOF through site-directed mu-
tagenesis. Protein was generated from cDNA expressing the 
identified Apert syndrome mutations and complexed with FGF2 
ligand. The resulting complexes were then purified and crysta-
llised. Both receptor mutations appeared to augment ligand-re-
ceptor interaction affinity, providing evidence for a clinical GOF 
model.4
A similar body of evidence supports GOF mutations in the FG-
F3R transcellular domain in achondroplasia and the FGF3R ex-
tracellular domain in thanatophoric dysplasia type II patients.1 
Are Genetic Errors Accumulated or Selected? 
A well-documented characteristic of FGFR syndromes is a pa-
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ternal age effect. This stipulates that syndrome incidence in-
creases with the age of the father at the time of conception. 
Thus, a paternal inheritance was hypothesised. The presen-
ce of two polymorphic base substitutions flanking the Apert 
mutation loci enabled the design of allele-specific primers for 
polymerase chain reaction (PCR), comparing the haplotype of 
the affected allele in patients to those of their parents. Original 
experimentation identified 57/57 families showed mutations 
linked to the paternal allele and thus paternal inheritance.5 
This exclusivity is apparent in all further published studies to 
date. 
A prevailing hypothesis therefore speculated that the basis of 
paternal inheritance lay in the accumulation of replication-de-
pendent mutations in spermatogonia over time, leading to an 
increased frequency of mutations with paternal age and a re-
sulting greater likelihood of mutated spermatozoal fertilisation. 
This is the copy-error hypothesis.6,7  
However, a fortunate experimental tool emerged when it was 
discovered that the Apert mutation loci encompass the res-
triction site for the enzyme Microtubule organizer protein 1 
(Mbo1). Therefore, through the development of PCR primers 
spanning this site, in non-mutated DNA there would be no am-
plification following treatment by Mbo1 due to cleavage and 
prevention of primer annealing whilst in mutated DNA amplifi-
cation would still occur. As such, mutation prevalence could be 
estimated. 6 In spermatozoa samples taken from normal men, 
mutation rate did not appear to vary significantly when asses-
sed over days, weeks or months. This implicated that muta-
tions were not accumulating over time. However, spermatozoa 
mutation level was positively correlated with age. Further, the 
mutation was likely pre-meiotic since if it was post-meiotic we 
would expect a reduction in mutation level with loss of sper-
matozoa over time.6 Inaccuracy is present within this experi-
mental protocol as PCR itself introduces mutations; the efficacy 
of the restriction enzyme is not 100% and any mutation within 
the restriction site irrespective of whether it is specific to Apert 
syndrome would show as positive. Despite these limitations, 
this experimentation still provides strong evidence opposing 
the copy-error theory.6
Further experimentation by the group utilised the same Mbo1 
based technique. This illustrated that the serine-tryptophan 
transversion was approximately 19-fold more common than 
other mutations, thus being disproportionately high. They rea-
soned that within a male heterozygous for the adjacent poly-
morphism to the Apert mutation locus, if the mutation was 
random and accumulating it would be expected that mutations 
would be equally divided between each polymorphic variant. 
However, the group identified that the relative distribution was 
skewed. Through the use of reverse transcription PCR (RT-PCR) 
analysis, expression of FGF2R RNA was confirmed in rat sper-
matogonial stem cells.7 Thus, this body of evidence argues for 
the presence of a selection process for the FGFR GOF mutation 
within the testis. Expression within spermatogonial stem cells 
is a pre-requisite for selection, suggesting selection at the pro-
tein level. As such, a novel hypothesis was born.  
Spermatogonia are the basis of the stem cell capacity of the 
testis. It was originally unclear whether the entire population 
possessed this capacity, or whether a subset drove spermato-
genesis. Through the use of genetic engineering in the mouse 
testis, spermatogonia can be irreversibly labelled such that 
their offspring express traceable lineage markers following ex-
posure to tamoxifen. When pulsed with the drug, the majority 
of labelled spermatozoa were lost by 2 months, due to disso-
ciation from the seminiferous tubule and maturation processes 
in the epididymis. However, a small fraction of positive cells 
appeared to persist beyond 3 months, producing an average of 
6.1 patches per testis. Utilising a similar genetic labeling sys-
tem, the group then went on to show that cells isolated from 
these colonies, when transplanted to recipient testes, could 
form de novo colonies and resulting spermatozoa, indicating 
a stem cell capacity.8 This experimentation presents essential 
evidence in supporting a selection hypothesis within the testis. 
It argues for the presence of an original ‘actual stem cell’ popu-
lation generating spermatogonia which then go on to differen-
tiate, forming spermatozoa. It implicates that a subset of the 
generated spermatogonia will become ‘potential stem cells’, 
deriving colonies which themselves are able to proliferate and 
differentiate. Thus, if a spermatogonial stem cell population 
was to acquire advantageous genetic traits, it could drive selec-
tive mechanisms through potential stem cell colony formation. 
The frequency of the most common Apert mutation is 100-1,000 
times higher than would be expected from average background 
mutation rate. Qin et al., 2007 published pioneering experi-
mentation to examine the spatial distribution of mutated sper-
matogonia by dividing the testes of two normal men into 200 
segments and quantifying the mutation frequency within each 
segment utilising PCR. This identified foci of mutation frequen-
cy 1,000-10,000 fold higher than underlying testis tissue.9 This 
experimentation argues for the rejection of a hypothesis that 
higher mutation rates in older men are associated with Apert 
syndrome mutation ‘hot-spots’ (loci prone to mutagenesis). It 
is highly suggestive of the selection hypothesis with mutation 
foci analogous to the aforementioned potential stem cell po-
pulations.8
The ‘Selfish Testis’ and Beyond
Mouse modelling of Apert syndrome has been achieved uti-
lising CreLox recombination technology to generate a targe-
ted serine-tryptophan mutation within the FGF2R. This animal 
model has been intrinsic in establishing downstream effector 
mechanisms mediating pathogenesis. Through the use of RNA 
interference knockdown of the mutated allele in mice hete-
rozygous for the Apert mutation, Shukla et al., 2007 illustrated 
that ERK1/2 levels were normalised at the RNA and protein 
level compared to enhanced expression seen in mutant ani-
mals. These members of the mitogen activated protein tyrosine 
kinase family (Figure 1) were thus strongly implicated as me-
diators at the molecular level of GOF FGFR mutations. Treatment 
of mutant mice with U0126, an inhibitor blocking activation of 
the extracellular signal-regulated kinase (ERK) pathway, facili-
tated birth of morphologically normal mice when injected into 
pregnant mothers, further supporting this pathogenic mecha-
nism.10-12 Thus, it is apparent that activating FGFR mutations 
appear to drive mitogenic pathways within affected cells.  
FGFR activating mutations have been identified within a range 
of tumour types. This is particularly apparent in the context of 
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endometrial carcinoma. Through sequencing endometrial can-
cer cell DNA from cell lines and primary uterine tumours, it 
has been identified that 30% and 10% of cancers, respectively, 
expressed varying FGFR activating mutations. These included 
those identified in congenital syndromes such as Apert syndro-
me and achondroplasia.13 Comparable data has been reported 
in further studies with sequencing and mass spectrometry of 
endometrial cancers identifying 12.3% with FGF2R mutations, 
including those mediating Apert syndrome. Similar mutations 
have been identified within a range of tumour types including 
myeloproliferative disease, gastric, squamous cell, small cell 
lung and breast cancers.14  
The concepts of mutation selection within the spermatogonia 
of the testis in addition to the probable involvement of mito-
genic pathway activation are reminiscent of the apparent in-
volvement of oncogenic mutations in the tumours discussed. 
Therefore, it was proposed that such mutations could drive tu-
morigenesis directly within the testis. Classical seminoma germ 
cell tumours do not show the correct epidemiological charac-
teristics for paternal age effect mutations. However, sperma-
tocytic seminomas, a rarer neoplasm, commonly affect older 
men. Through sequencing FGFR mutation hot-spots within 30 
samples of tumours, two were identified as having GOF FGF3R 
mutations previously identified in thanatophoric dysplasia II. 
Similar mitogenic pathway regulators such as Harvey rat sar-
coma viral oncogene homolog (HRAS), a factor associated with 
congenital Costello syndrome characterised by skeletal and vis-
ceral morphological defects and mental retardation, were also 
identified with GOF mutations in spermatocytic seminomas.15 
This body of evidence proposes that GOF mutations in sperma-
togonia induce selective advantage and clonal expansion, dri-
ving in situ testis tumorigenesis. However, a prominent caveat 
of this experimentation, in addition to those assessing muta-
tion profiles in varying tumours, is the retrospective nature of 
the studies with no conclusive evidence that the mutations 
identified are causative. FGFR GOF as such could represent ac-
quired mutations within the neoplasm, selected for by mitoge-
nic advantage and acquired after the original pathogenic event. 
Despite this, the work presents a viable theory of a spectrum 
of pathology with a common FGFR GOF aetiology. Further, a 
novel, interesting concept in the form of the ‘selfish testis’ is 
portrayed.16 FGFR GOF mutations appear to drive a selective 
advantage within the testis (spermatogonium) itself but when 
transmitted to the resulting offspring they induce defects in 
growth and cellular division due to imbalances in activating 
signals. Thus, the testis appears ‘selfish’ in selecting for an 
intrinsically beneficial mutation that becomes detrimental in 
the fetus.
A Pathological Spectrum and Multigenic Risk 
If we envisage FGFR mutations as a hypothetical spectrum with 
grades of activation capacity, it is possible to classify the afo-
rementioned pathological outcomes. ‘High activating’ FGFR GOF 
mutations would be detrimental when acquired within the tes-
tis and other tissues implicated in tumorigenesis. ‘Moderately 
activating’ mutations would show the same selection mecha-
nisms within the testis, but have negligible pathogenesis in 
situ, acting as the pathogenic agent in congenital syndromes 
within resulting offspring. A prominent question, therefore, be-
comes ‘what of ‘low activating’ mutations: Do they exist and 
are they pathogenic?’ 
Unilateral segmented acne in a mosaic pattern has previous-
ly been described as a dermatological hallmark of Apert sy-
ndrome.17 However, this disease has also been identified in 
patients without the classical Apert syndrome presentation. 
Within one such patient, sequencing of the FGF2R gene in 
cells isolated from the naevus demonstrated an identical seri-
Figure 1. Fibroblast Growth Factor Receptor Cellular Signalling
Adapted from: Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 1995;9(9):726-35; Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast 
growth factor receptors. Cytokine Growth Factor Rev. 2005;16(2 SPEC. ISS.):139-49.
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ne-tryptophan GOF mutation characteristic of Apert syndrome. 
Other dermatological stigmata associated with this mutation 
include hypopigmentation and hypotrichosis (loss or reduc-
tion of hair growth).17 Therefore, this discovery presents two 
important concepts: Firstly, despite this patient presenting 
with an acquired FGFR mutation, as opposed to the congenital 
forms of systemic disease previously described, the resulting 
findings affirm that GOF underlies the pathological features of 
Apert syndrome. Secondly, it illustrates that such mutations 
can alter the equilibrium of tissues constitutively regenerating 
throughout life, leading to defects in structure and integrity. 
Thus, it is pertinent to question whether alternative variants of 
the FGFR, other than those described in congenital syndromes, 
could contribute to numerous disease aetiologies - particularly 
in tissues with renewing capacity.
Single nucleotide polymorphisms (SNPs), as DNA sequence va-
riations occurring at a single base, provide an ideal tool to 
assess the viability of this hypothesis. Breast tissue retains 
proliferative capacity throughout life, particularly in response 
to hormonal change. Genome wide sequencing within breast 
cancer tissue specimens has identified that variation in FGF2R 
loci, linked to eight SNPs, is associated with a small but sig-
nificant increased risk of developing breast cancer. Microarray 
data confirmed by real-time quantitative PCR illustrated that 
within rare homozygous cells for these SNPs there is amplifi-
cation of FGF2R expression at the RNA level. Chromatin immu-
noprecipitation ascertained that two of the SNPs resulted in an 
increased association of FGF2R DNA with transcription factors 
such as Oct1 that are known to be associated with proliferative 
capacity and tumorigenesis. Therefore, this provides a putative 
mechanism by which sequence variation in the FGF2R can dri-
ve increased expression, effectively representing a GOF of the 
receptor and resulting in tumorigenesis.18 
The epithelial lining of the mouth and oropharynx also main-
tain a regenerative capacity. A specific SNP within FGF4R has 
previously been associated with increased tumour cell motility 
and progression within breast, head and neck, and sarcoma 
cancers. Recent experimentation has focussed on the prognos-
tic significance of SNP presence in squamous cell carcinoma 
of the mouth and oropharynx. Through genotyping DNA from 
peripheral blood samples of 122 patients and assessing pro-
tein expression by immunohistochemistry in tumour cells, SNP 
presence was associated with lymphatic embolisation and di-
sease-related premature death. Thus, the SNP appears linked 
with poor prognosis, a phenomenon which has previously been 
illustrated in a variety of tumours including lung and prostate 
cancers.19  
These experiments do, however, exhibit multiple caveats. 
Neither establishes a direct causative link between the SNPs 
studied and tumour formation based on their retrospective 
nature. Further, in assessment of FGF4R prognostic value, the 
treatment regimens of patients and their responses to thera-
peutic intervention cannot be adequately controlled between 
SNP positive and negative groups. In addition, the functional 
outcome induced by SNP presence has as yet not been cha-
racterised, so links to GOF have not been established. Never-
theless, the experimental data presented does illustrate that 
genetic variation, even at levels as low as a single base, can 
alter function of the receptor complex and contribute risk to 
the formation and outcome of varying pathologies. Therefore, 
it is plausible that these polymorphisms represent a category 
of ‘low activating’ mutations, predisposing to increased disea-
se burden within affected populations. It remains to be esta-
blished whether SNP derivation illustrates the same selection 
mechanisms within the testis as seen in the GOF mutations 
discussed, which would be required to justify this assertion. 
Further, the degree of disease association and the range of 
implicated pathologies are still to be ascertained. However, this 
hypothesis signifies an exciting prospect, putatively represen-
ting an underlying principle, which will be essential in unra-
velling the complex issue of multigenic risk factors in disease 
aetiology over the coming decades.
Conclusion
FGFR GOF mutation is implicated in numerous pathologies. By 
visualising GOF as a spectrum of activity and studying genetic 
polymorphism we can speculate that such genetic traits confer 
alteration in FGFR function and thus contribute to multigenic 
disease risk. 
To prove this hypothesis, however, a number of questions re-
main to be answered. Although a spectrum of activation provi-
des an attractive model that conceptually relates genotype to 
the clinical phenotypes produced, a direct comparison of the 
degree of GOF in each pathology and predisposition is required. 
This includes assessment of RNA and protein amplification in 
addition to the strength of ligand-receptor complex formation. 
Further, selection of SNPs and other mutations related to di-
sease risk need to be confirmed. Finally, although the studies 
presented centre on tumorigenesis due to the mitogenic activa-
tion induced by FGFR GOF mutation, relation to other common 
morbidities including cardiovascular, endocrine and autoimmu-
ne disorders provides an important area of study.
Can this basic science impact on clinical outcomes? Is there a 
plausible bench-to-bedside application of this evidence? Preim-
plantation genetic screening for in vitro fertilisation is perfor-
med for numerous pathologies including Huntington’s disea-
se and cystic fibrosis as well as genetic predispositions such 
as BRCA1/2 mutation. Were FGFR risk factors to be confirmed, 
inclusive screening programmes could be developed. Further, 
as GOF is inherited paternally, offspring are commonly hete-
rozygous. Thus, targeted genetic therapies such as antisense 
oligonucleotide-mediated knockdown or RNA interference knoc-
kdown specifically against the mutated allele are feasible. With 
the advent of these technologies, our continued understanding 
of FGFR contribution to multigenic disease could spark progress 
in reducing clinical disease incidence and burden.
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